Tech Company Financing Transactions
HDT Bio Funding Round
HDT Bio, based in Seattle, raised $3 million from Zoic Capital and private investors.
Transaction Overview
Company Name
Announced On
10/6/2020
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Seed
Investors
Zoic Capital (Lead Investor)
Proceeds Purpose
The company intends to use the funds for the continued development of its COVID-19 vaccine candidate, HDT-301. The vaccine is slated to enter clinical trials in Q4 2020 in partnership with the NIH/NIAID.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1616 Eastlake Ave. E 280
Seattle, WA 98102
USA
Seattle, WA 98102
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
HDT Bio, was launched in 2018 after 25 years of success within infectious disease research and development from the Infectious Disease Research Institute (IDRI). IDRI has gained a reputation as being one of the few institutions worldwide that has the capacity to take an idea for a global health solution from the very early stages of basic research all the way through commercialization with key partners.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steve Reed
Chief Operating Officer
Christopher Pirie
Chief Scientific Officer
Darrick Carter
Chief Technical Officer
Peter Berglund
Browse more venture capital transactions:
Prev: 10/6/2020: Scener venture capital transaction
Next: 10/6/2020: Cooler Screens venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs